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selective antagonist significantly inhibits neointimal for-
mation in cultured human saphenous vein,8 suggesting
that it is the ET-B receptor that plays a pivotal role in the
development of human venous IH. The precise mecha-
nism by which ET-1 facilitates vascular lesion formation
remains to be fully elucidated.
ET-1 is synthesized from an inactive 38-amino acid pre-
cursor, big ET-1, by specific proteolytic cleavage. The
enzyme responsible for this last step of posttranslational pro-
cessing of big ET-1 is a membrane-bound zinc metallopro-
tease, endothelin-converting enzyme-1 (ECE-1).9 Inhibition
of ECE-1 would be expected to suppress the production of
ET-1 and, hence, its pathophysiologic effects. Inhibition of
ECE is therefore an attractive therapeutic target.
Inhibitors of ECE have been reported, but all the
compounds described to date also have neutral endopep-
tidase 24.11 (NEP) activity. This observation is not sur-
prising because NEP is known to be a membrane-bound
zinc metalloprotease that shares 37% amino acid sequence
identity with ECE-1.10 It is also thought that ECE-1 and
NEP share a high degree of homology in their active
sites.11 NEP cleaves a number of substrates, including ET-
1,12 so inhibitors of NEP may actually raise ET-1 levels.
Although the structures of ECE and NEP exhibit a strik-
Endothelin-1 (ET-1) is a 21-amino acid peptide pro-
duced primarily by vascular endothelial cells with potent
mitogenic activity for vascular smooth muscle cells
(SMCs).1 A potential role for ET-1 in the development of
intimal hyperplasia (IH) in human vessels is suggested by
means of the finding that ET-1 is mitogenic for saphenous
vein SMCs2 and that increased ET-1 expression can be
detected in vein graft stenoses.3 Two main receptor sub-
types for ET-1 have been characterized and designated
ET-A and ET-B.4,5 Considerable interest has been directed
to the potential of endothelin antagonists as therapeutic
agents,6,7 resulting in the development of a large number
of both selective and nonselective compounds. In our own
laboratory, we have shown that a nonselective or an ET-B
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Purpose: Endothelin-1 (ET-1) has been implicated in a variety of vascular pathologic conditions, although there is con-
siderable controversy as to whether such effects are mediated by the ET-A or ET-B receptor. This study investigated
whether inhibition of big ET-1 processing by inhibition of endothelin-converting enzyme (ECE) could, therefore, offer
an alternative therapeutic strategy in the prevention of vein graft intimal hyperplasia.
Methods: Human saphenous vein (3 equal segments from 10 patients) were maintained in organ culture for 14 days with
either 50 µmol/L CGS 26303 (a dual ECE/neutral endopeptidase [NEP] inhibitor), 50 µmol/L CGS 24592 (a selec-
tive NEP inhibitor), or vehicle (control). They were then processed for immunostaining and neointimal thickness mea-
surements, and conditioned media was collected for enzyme-linked immunosorbent assay analysis.
Results: Neointimal thickness in the ECE/NEP-inhibited veins did not differ significantly from that of control seg-
ments. However, there was a highly significant augmentation in the NEP-inhibited segments, consistent with an inhi-
bition of ET-1 degradation (median difference, 16.8; 95% CI, –23.5, –10.4; P = .002, Wilcoxon). ECE immunostaining
was reduced in the ECE/NEP-inhibited veins, although ET-1 staining was also present. ET-1 expression was intense
in the thickened neointimas of NEP-inhibited veins, which also showed significant ECE staining. Elevated levels of big
ET-1 were measured in the ECE/NEP-inhibited veins, consistent with reduced ECE activity. However, mature ET-1
was still detectable in these segments.
Conclusion: There is a requirement for potent and selective inhibitors of ECE to evaluate fully the potential therapeu-
tic benefits of blocking ET-1 biosynthesis. The use of dual inhibitors complicates the interpretation of results, because
the observed response is likely to be a combination of both ECE and NEP inhibition. (J Vasc Surg 2001;34:548-54.)
ing similarity, they are remarkably different in their cleav-
age site specificity. NEP rapidly degrades mature ET-1 at
multiple cleavage sites, whereas, in contrast, ECE is highly
specific for the cleavage of the Trp21-Val22 bond of big
ET-1. Furthermore, ECE is generally regarded to be
insensitive to NEP inhibition.13 Many selective inhibitors
of NEP have been described9,14; therefore, ECE and NEP
may be distinguished by the use of a potent inhibitor of
NEP that is ineffective against ECE.9,14
In this study, we compare the effect of two competi-
tive inhibitors, CGS 26303, a dual inhibitor displaying
modest inhibition of ECE in vitro with a potent effect on
NEP,15 and CGS 24592, a selective inhibitor of NEP16 on
the development of neointima in an organ culture of the
human long saphenous vein.17 This is a well-validated lab-
oratory model of human venous IH, in which vessels
develop a cellular neointima that shares many of the char-
acteristics of the stenotic lesions that occur in vivo.18
Although IH is undoubtedly a multifactorial process that
involves numerous autocrine and paracrine mechanisms,
our earlier in vitro results with ET receptor antagonists
have achieved greater reductions in neointimal thickness
than any other pharmacologic agent.8 We therefore pro-
pose that inhibition of big ET-1 processing by means of
suppressing ECE activity may offer a potential therapeutic
target in the amelioration of human saphenous vein IH.
METHODS
Vein culture. Segments of the long saphenous vein
were obtained from 10 patients undergoing arterial bypass
grafting. Freshly obtained specimens were immediately
transported to the laboratory and prepared for culture by
means of a method described earlier.18 In brief, the veins
were opened longitudinally and cut into 0.5-cm lengths.
Each segment was pinned, with the luminal surface upper-
most, onto a 500-µm mesh that rested on a layer of pre-
formed Sylgard resin (Dow Corning, Seneffe, Belgium) in
the bottom of a 60- by 20-mm glass petri dish. This
method of vein culture has been reported17-19 and exten-
sively validated in our own laboratory as a representative
in vitro model of the changes that occur in vein grafts in
vivo.18 Cultures were maintained in RPMI 1640 medium
(Northumbria Biologicals, Cramlington, UK) and supple-
mented with 30% fetal calf serum (Seralab, Crawley
Down, UK) for 14 days at 37°C in a humidified atmos-
phere of 5% CO2 in air.
Three consecutive segments were prepared from each
vein specimen and randomized to the various treatment
groups. In each group, one segment served as a control
(vehicle only), and we added either the dual ECE/NEP
inhibitor CGS 26303 (50 µmol/L) or the selective NEP
inhibitor CGS 24592 (50 µmol/L) to the remaining two
segments. Our choice of drug concentration was derived
from a cell culture study, in which the range of concentra-
tions used for both compounds were 10 µmol/L to 1
mmol/L.16 No signs of decreased viability were observed,
and significant effects on ET-1 in the culture media were
observed at both 10 µmol/L and 100 µmol/L after a 10-
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hour period. We therefore conducted a preliminary study
incubating human saphenous vein SMCs in culture
medium or in medium supplemented with 50 µmol/L of
either compound. After a period of 7 days, drug-treated
SMCs were morphologically indistinct from control SMCs
and more than 95% viable when assessed by means of tryp-
an blue exclusion (unpublished observations).
The culture medium and drugs were replaced every 2
to 3 days, and samples of conditioned medium were col-
lected and snap-frozen for subsequent quantification of
big ET-1 and ET-1. After 14 days, while still pinned in the
culture dishes, the segments were fixed overnight in 10%
formalin solution, processed, and paraffin-embedded.
Immunohistochemistry. The paraffin-embedded
vein segments were serially cut into 4-µm sections and
slide mounted. Randomly selected sections were stained
with a combined monoclonal anti–smooth muscle α-actin
(Dako, High Wycombe, UK) and Millers elastin (SMA/
Millers).19 This staining procedure allows precise localiza-
tion of SMCs and elastic fibers in the vessel wall and,
hence, the identification of the different layers of the vein
wall (media, intima, and neointima).
Further serial sections from each treatment group
were stained with monoclonal anti-human ET-1 antibody
at 1:200 (clone TR.ET.48.5, Cambridge Bioscience, UK),
or an antihuman ECE-1 monoclonal antibody AEC32-
236 at 40 µg/mL (a gift from Professor K. Tanzawa,
Sankyo Pharmaceuticals, Tokyo, Japan). All the immuno-
staining procedures were carried out with the avidin-
biotin (ABC) technique, with diaminobenzidine as the
final reaction product.
Semiquantitative analysis of ET-1 and ECE-1.
Transverse sections of vein segments stained for ET-1 and
ECE were examined by two independent observers who
were “blind” to results for cellular localization and inten-
sity of staining. They were scored semiquantitatively: 0, no
staining; 1, weak positive staining; 2, moderate positive
staining; or 3, strong positive staining.
Measurement of neointimal thickness. Measure-
ments of neointimal thickness were made on transverse sec-
tions of each vessel stained with SMA/Millers that enabled
clear delineation of the neointima. With a computerized
image analysis system (Improvision, Coventry, UK), 30
measurements, evenly distributed across the whole section,
were made on each vein. Measurements were performed
by two independent observers and showed a high level of
agreement (interobserver error). Additionally, the mea-
surements for any one section were found to be both con-
sistent and reproducible (intraobserver error).20
Enzyme-linked immunosorbent assay. Enzyme-
linked immunosorbent assay (ELISA) measurements of
big ET-1 and ET-1 were performed on media collected
between days 8 and 10 of culture. We have shown that, in
the 14-day culture period, this is the time of “peak” lev-
els in the medium (unpublished observations) and occurs
concomitantly with maximum proliferative activity in the
neointima.17 Because ET-1 is preferentially secreted ablu-
minally,21 changes in levels in the conditioned medium
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are indicative of significant changes within the vein wall
itself.
For measurement of big ET-1 and ET-1 levels in the
conditioned medium, we used commercially available sand-
wich ELISA assays (Biomedica, Vienna, Austria). Both assays
use a highly specific purified polyclonal capture antibody and
a monoclonal detection antibody. For the ET-1 assay, the
cross-reactivity with big ET-1 is less than 1%, and for big 
ET-1, the cross-reactivity with ET-1 is also less than 1%.
Frozen aliquots were thawed over ice and assayed
according to the manufacturer’s protocol.
Statistics. All neointima summary data are expressed
as the median and range. Differences in neointimal thick-
nesses were analyzed by using a Wilcoxon paired rank test,
with 95% CIs.
Summary data for the ELISA analyses are expressed as
the mean and range. Differences in the levels of big ET-1
and ET-1 were analyzed with a Student t test.
RESULTS
Neointimal thickness. Representative histologic sec-
tions of vein segments stained with SMA/Millers are
shown in Fig 1. All control veins developed a significant
neointima, with a median thickness of 17.2 µm (range,
Fig 1. Representative transverse sections of vein segments stained with SMA/Millers elastin. Control veins (a) devel-
oped thickened neointimas (arrows), which were not significantly different from veins treated with combined ECE/NEP
inhibitor CGS 26303 (b). Vein segments treated with selective NEP inhibitor CGS 24592 (c) developed significantly
thicker neointimas than both control (P = .002) and dual ECE/NEP-inhibited groups (P = .01, Wilcoxon paired rank
test; original magnification, ×160).
Fig 2. Scatter plot showing neointimal thickness measurements
of veins from various treatment groups (n = 10). Dual ECE/NEP
inhibitor CGS 26303 had no effect on neointimal thickening,
compared with controls. Selective NEP inhibitor CGS 24592 sig-
nificantly augmented neointima formation (P = .002). Horizontal
bars represent median value for each treatment group.
12.7-24.2 µm). The median neointimal thickness of veins
treated with the selective NEP inhibitor was 33.3 µm
(range, 19.6-50.6 µm). The median difference was 16.8
(95% CI, –23.5, –10.4; P = .002). The median neointimal
thickness of veins treated with the combined ECE/NEP
inhibitor was 20.0 µm (range 11.1-47.1 µm), which was
not significantly different from that of the control group.
However, the median neointimal thickness of the com-
bined inhibitor group was significantly less than the group
treated with the pure NEP inhibitor. The median differ-
ence was 13.95 (95% CI, –20.7, –3.6; P = .01). These
results are summarized as a scatter plot in Fig 2.
Immunohistochemistry. Vein sections were graded
on intensity of immunostaining for ECE and ET-1.
Control veins showed moderate staining for ECE (grade
2), compared with weak staining in the ECE/NEP-inhib-
ited group (grade 1). ECE staining in the NEP-inhibited
group was similar to that observed in control segments
(grade 2). Representative vein segments stained for ECE
are presented in Fig 3.
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ET-1 staining was moderate in the control segments
(grade 2), weak/moderate in the ECE/NEP-inhibited
group (grade 1/2), and intense in the NEP-inhibited
group (grade 3). Representative stained segments are
shown in Fig 4.
ELISA measurement of big ET-1 and ET-1. We
have observed that SMC proliferation is greatest in this
model between days 7 and 14 of culture.17 We therefore
measured levels of big ET-1 and ET-1 in the conditioned
medium collected between the 8th and 10th day of cul-
ture. Measurements are expressed as femtomoles per mil-
liliter per 24 hours (fmol/mL/24 h).
The mean level of big ET-1 in the conditioned medium
of control veins was 2.03 (range, 0.7-3.0) and was signifi-
cantly elevated in the ECE/NEP-inhibited group to 3.7
(range, 2.5-5.5; P = .026). Big ET-levels in the NEP-inhib-
ited group were not significantly different from those of the
control group, with a mean value of 1.9 (range, 0.5-4.0).
Control group ET-1 levels were 1.75 (range, 0.4-2.8),
compared with 0.82 (range, 0.4-1.2) in the ECE/NEP
Fig 3. Transverse sections of vein immunostained for ECE-1. a, Positive staining (grade 2) can be observed in endothe-
lial and neointimal SMCs of control veins (arrows). b, Significantly reduced staining (grade 1) was observed in
ECE/NEP-inhibited group. c, Positive staining for ECE (grade 2/3) is also present in endothelial and neointimal SMCs
of NEP-inhibited veins (arrows; original magnification, ×160).
inhibited group, but they just failed to reach statistical sig-
nificance (P = .056). However, ET-1 levels in the NEP-
inhibited group were significantly elevated at 3.7 (range,
2.4-6.5; P = .04). These results are presented as a bar
graph in Fig 5.
DISCUSSION
In this study we used two structurally related nonpep-
tide compounds, CGS 26303 and CGS 24592. CGS
26303 exhibits ECE inhibitory activity with an IC50 of 1.1
µmol/L and inhibits NEP with an IC50 of 1 nmol/L. CGS
24592 inhibits NEP with an IC50 of 1 nmol/L and does
not inhibit ECE. Although little progress has been made in
the design and development of selective ECE inhibitors,
the need for such agents has been confirmed by means of
this study. In this study, we found that CGS 26303 had no
effect on neointima formation. Although elevated levels of
big ET-1 were measured in the conditioned medium, sug-
gesting an inhibition of ECE, mature ET-1 was also pre-
sent, albeit in reduced quantities compared with that in
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control veins. The NEP inhibitory activity of the com-
pound would then maintain ET-1 levels and potentiate
neointimal SMC proliferation. This explanation is sup-
ported by the observation that the selective NEP inhibitor
CGS 24592 actually raised ET-1 levels and increased
neointimal size in this model.
Our results are consistent with those of earlier studies,
in which NEP inhibitors potentiated the levels of ET-1 in
cell culture supernatants16 and increased ET-1–induced
SMC contractility in strips of guinea pig lung.22 It is there-
fore reasonable to associate increased ET-1 levels in our
conditioned media with an augmentation of neointimal
thickness. Furthermore, we have shown that ET-1 stimu-
lates SMC proliferation in vitro and induces IH in organ-
cultured human saphenous vein.2 A significant reduction
in staining for ECE with a concomitant reduction in stain-
ing intensity for ET-1 was revealed by means of scoring of
the immunostainedvein segments from the combined
treatment group. These observations, taken as a whole,
support our hypothesis that the combined effect of CGS
Fig 4. Transverse sections of veins immunostained for ET-1. a, Control veins show endothelial and neointimal SMCs
staining positively (grade 2) for ET-1 (arrows). b, There is less staining (grade 1/2) in ECE/NEP-inhibited group, com-
pared with very intense staining (grade 3) in NEP-inhibited group (c; original magnification, ×160).
26303 on ECE and NEP inhibition results in no net effect
on neointima formation. However, NEP has a broad
selectivity, cleaving short linear or cyclic peptides and pep-
tides of intermediate or long length. It is possible, there-
fore, that in addition to increasing endothelin levels, NEP
inhibition may increase levels of angiotensin II, which has
been shown to be important in the development of IH in
organ-cultured human saphenous vein.23
Investigators of several studies have reported the
expression of ECE in rat arterial injury models,24,25 in
human transplant arteriosclerosis,26 and in human coro-
nary atherosclerosis.24 However, none to date have exam-
ined human saphenous vein. In agreement with an earlier
study, we have shown that ECE and ET-1 staining is
detectable in the endothelium and SMCs of the entire
thickened neointima but not in the media. One could sug-
gest from these observations that the increase in ECE and
ET-1 expression in the cultured vein is attributable to the
neointimal SMCs, and, therefore, the expression of ECE
probably depends on the phenotypic change of the SMCs
from contractile to synthetic.
The effects observed in this study occurred within 14
days; however, the neointima that develops in control
veins bears many of the features of the pathologic lesion of
stenosis that develops in several months in vivo.18 The
results presented in this study do not address the potential
long-term effects of SMC activity. This issue might be
addressed more appropriately in a longer study with an
animal model.
In conclusion, although little progress has been made
in the development of selective ECE inhibitors, there
remains a need for such agents. In conditions character-
ized by neointima formation, such as arterial bypass
grafting, treatment with a dual ECE/NEP inhibitor is
likely to compound the clinical problem. Because ET-1 is
a substrate for NEP,12 inhibition of NEP will actually
raise ET-1 levels. Any studies with dual inhibitors will, by
their very nature, be complicated because the observed
response could be caused by ECE inhibition, NEP inhi-
bition, or both. This study supports this conclusion and
confirms that without selective ECE inhibitors the
potential therapeutic benefit of blocking ET-1 biosyn-
thesis cannot be validated. In an earlier study, we showed
that an ET receptor antagonist can inhibit neointima for-
mation in this model.3 The use of this antagonist in com-
bination with CGS 24592 might further support a direct
role for ET-1 in intimal hyperplasia, if the increase in
neointimal thickness were abrogated. More recent work
has focused on the design of potent and selective ECE
inhibitors without NEP inhibitory activity.27 Future
studies with such selective compounds may, therefore,
assist in determining the involvement of overproduction
of ET-1 in vein graft IH.
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